

Joshua M Sharfstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7198672/publications.pdf>

Version: 2024-02-01

149
papers

2,736
citations

279487

23
h-index

223531

46
g-index

149
all docs

149
docs citations

149
times ranked

3765
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | A cross-sectional analysis of trends in dermatology practice size in the United States from 2012 to 2020. Archives of Dermatological Research, 2023, 315, 223-229. | 1.1 | 4 |
| 2 | Sharing the Media Spotlight—Communicating About Medical Products in Development During the Pandemic. JAMA Health Forum, 2022, 3, e215246. | 1.0 | 0 |
| 3 | The Patchwork U.S. Public Health System. New England Journal of Medicine, 2022, 386, 1-4. | 13.9 | 15 |
| 4 | Assessment of Public Opinion on Transparency at the US Food and Drug Administration. JAMA Network Open, 2022, 5, e220026. | 2.8 | 1 |
| 5 | Long-Acting Cabotegravir for HIV Prevention. JAMA - Journal of the American Medical Association, 2022, 327, 921. | 3.8 | 16 |
| 6 | Incentives for COVID-19 vaccination. The Lancet Regional Health Americas, 2022, 8, 100205. | 1.5 | 17 |
| 7 | US Suicide Rates and Impact of Major Disasters Over the Last Century. primary care companion for CNS disorders, The, 2022, 24, . | 0.2 | 3 |
| 8 | Global Compassionate Use—A New Lens on a Long-standing Inequity. JAMA Health Forum, 2022, 3, e220500. | 1.0 | 0 |
| 9 | Battling Falsehoods in the COVID-19 Pandemic. JAMA Health Forum, 2022, 3, e221587. | 1.0 | 11 |
| 10 | Effectiveness of vaccination mandates in improving uptake of COVID-19 vaccines in the USA. Lancet, The, 2022, 400, 535-538. | 6.3 | 27 |
| 11 | The COVID-19 Pandemic: An Opportunity to Transform Higher Education in Public Health. Public Health Reports, 2021, 136, 23-26. | 1.3 | 8 |
| 12 | “This Level of Death, It’s New”—Health Care Workers in Their Own Words. JAMA - Journal of the American Medical Association, 2021, 325, 331. | 3.8 | 3 |
| 13 | The US Regulatory System and COVID-19 Vaccines. JAMA - Journal of the American Medical Association, 2021, 325, 1153. | 3.8 | 5 |
| 14 | Rethinking Payment and Incentives for a Healthy Early Childhood. Academic Pediatrics, 2021, 21, 225-227. | 1.0 | 1 |
| 15 | Announcing the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. Lancet, The, 2021, 397, 1165-1167. | 6.3 | 25 |
| 16 | The Pandemic and the Supply Chain: Gaps in Pharmaceutical Production and Distribution. American Journal of Public Health, 2021, 111, 635-639. | 1.5 | 34 |
| 17 | What the American Rescue Plan Means for Health Equity. JAMA Health Forum, 2021, 2, e210658. | 1.0 | 6 |
| 18 | Enhancing Community Engagement by Schools and Programs of Public Health in the United States. Annual Review of Public Health, 2021, 42, 405-421. | 7.6 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Extreme Risk Protection Orders—A Tool for Clinicians to Prevent Gun Violence. JAMA Health Forum, 2021, 2, e210948. | 1.0 | 2 |
| 20 | Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COVID.S Vaccine. JAMA - Journal of the American Medical Association, 2021, 325, 2445. | 3.8 | 20 |
| 21 | Identifying and Tracking SARS-CoV-2 Variants — A Challenge and an Opportunity. New England Journal of Medicine, 2021, 385, 389-391. | 13.9 | 14 |
| 22 | Child Health Policy and the COVID-19 Pandemic. JAMA Health Forum, 2021, 2, e212921. | 1.0 | 2 |
| 23 | Uncoupling vaccination from politics: a call to action. Lancet, The, 2021, 398, 1211-1212. | 6.3 | 53 |
| 24 | US Healthcare Policy and Child Poverty. Academic Pediatrics, 2021, 21, S88-S89. | 1.0 | 2 |
| 25 | Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. Lancet, The, 2021, 398, 2186-2192. | 6.3 | 106 |
| 26 | Product Approval and Public Health at the US Food and Drug Administration. JAMA - Journal of the American Medical Association, 2021, 326, 2469. | 3.8 | 2 |
| 27 | Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration. JAMA Internal Medicine, 2020, 180, 301. | 2.6 | 25 |
| 28 | Help Is on the Way: Medicare Coverage of Opioid Treatment Programs. Journal of the American Geriatrics Society, 2020, 68, 637-640. | 1.3 | 6 |
| 29 | Facilitating Methadone Use in Hospitals and Skilled Nursing Facilities. JAMA Internal Medicine, 2020, 180, 7. | 2.6 | 24 |
| 30 | Performance and Priorities: A Cross-sectional Study of Local Health Department Approaches to Essential Public Health Services. Public Health Reports, 2020, 135, 97-106. | 1.3 | 5 |
| 31 | Attacks on Public Health Officials During COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 741. | 3.8 | 58 |
| 32 | Resilience in Health Care Financing. JAMA - Journal of the American Medical Association, 2020, 324, 126. | 3.8 | 3 |
| 33 | The Role of Evidence in the US Response to the Opioid Crisis. Epidemiologic Reviews, 2020, 42, 167-170. | 1.3 | 2 |
| 34 | Critical Drugs for Critical Care: Protecting the US Pharmaceutical Supply in a Time of Crisis. American Journal of Public Health, 2020, 110, 1346-1347. | 1.5 | 3 |
| 35 | Reassuring the Public and Clinical Community About the Scientific Review and Approval of a COVID-19 Vaccine. JAMA - Journal of the American Medical Association, 2020, 324, 1296. | 3.8 | 21 |
| 36 | Public Opinion on the Sale of Crib Bumpers. JAMA Network Open, 2020, 3, e208089. | 2.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | The Urgency and Challenge of Opening K-12 Schools in the Fall of 2020. JAMA - Journal of the American Medical Association, 2020, 324, 133. | 3.8 | 61 |
| 38 | How Not to Spend an Opioid Settlement. JAMA - Journal of the American Medical Association, 2020, 323, 1031. | 3.8 | 4 |
| 39 | Additional Barriers to Methadone Use in Hospitals and Skilled Nursing Facilitiesâ€”Reply. JAMA Internal Medicine, 2020, 180, 615. | 2.6 | 2 |
| 40 | Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Programâ€”Reply. JAMA Internal Medicine, 2020, 180, 916. | 2.6 | 0 |
| 41 | Diagnostic Testing for the Novel Coronavirus. JAMA - Journal of the American Medical Association, 2020, 323, 1437. | 3.8 | 209 |
| 42 | Reform at the FDAâ€”In Need of Reform. JAMA - Journal of the American Medical Association, 2020, 323, 123. | 3.8 | 5 |
| 43 | Affording Genetic Therapies in the Medicaid Program. JAMA Pediatrics, 2020, 174, 523. | 3.3 | 3 |
| 44 | A Bold Response to the COVID-19 Pandemic. JAMA - Journal of the American Medical Association, 2020, 323, 1790-1791. | 3.8 | 80 |
| 45 | Analysis of Ingredients of Supplements in the National Institutes of Health Supplement Database Marketed as Containing a Novel Alternative to Anabolic Steroids. JAMA Network Open, 2020, 3, e202818. | 2.8 | 19 |
| 46 | Unexpected Health Insurance Profits and the COVID-19 Crisis. JAMA - Journal of the American Medical Association, 2020, 324, 1713. | 3.8 | 11 |
| 47 | Unexpected Health Insurance Profits and the COVID-19 Crisis. JAMA Health Forum, 2020, 1, e201094. | 1.0 | 2 |
| 48 | How the FDA should protect its integrity from politics. Nature, 2020, 585, 161-161. | 13.7 | 7 |
| 49 | Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers Within the Treatment System. NAM Perspectives, 2020, 2020, . | 1.3 | 90 |
| 50 | Resilience in Health Care Financing. JAMA Health Forum, 2020, 1, e200614. | 1.0 | 0 |
| 51 | â€œThis Level of Death, Itâ€™s Newâ€”Health Care Workers in Their Own Words. JAMA Health Forum, 2020, 1, e201551. | 1.0 | 0 |
| 52 | How Not to Spend an Opioid Settlement. JAMA Health Forum, 2020, 1, e200025. | 1.0 | 0 |
| 53 | Lessons Learned From the Opioid Epidemic. JAMA - Journal of the American Medical Association, 2019, 322, 809. | 3.8 | 16 |
| 54 | Private Equity and Dermatologyâ€”First, Do No Harm. JAMA Dermatology, 2019, 155, 1007. | 2.0 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Adolescence: An Opportunity for Population Health. <i>Milbank Quarterly</i> , 2019, 97, 926-929. | 2.1 | 0 |
| 56 | Introduction: State Innovation Models. <i>Milbank Quarterly</i> , 2019, 97, 505-505. | 2.1 | 0 |
| 57 | The Opportunity of CBD â€” Reforming the Law. <i>New England Journal of Medicine</i> , 2019, 381, 297-299. | 13.9 | 15 |
| 58 | Making Amends for the Opioid Epidemic. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1446. | 3.8 | 21 |
| 59 | The Promiseâ€”and Politicsâ€”of State Innovation for Health. <i>Milbank Quarterly</i> , 2019, 97, 387-390. | 2.1 | 0 |
| 60 | Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 676. | 3.8 | 30 |
| 61 | Evaluating the centralized purchasing policy for the treatment of hepatitis C: The Colombian CASE. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00552. | 1.1 | 6 |
| 62 | Comparison of US County-Level Public Health Performance Rankings With County Cluster and National Rankings. <i>JAMA Network Open</i> , 2019, 2, e186816. | 2.8 | 14 |
| 63 | The cost of the opioid epidemic, in context. <i>American Journal of Managed Care</i> , 2019, 25, S241-S242. | 0.8 | 2 |
| 64 | Commentary on â€”Revisiting the â€”paradigm shiftâ€” in opioid use: Developments and implications 10 years laterâ€”. <i>Drug and Alcohol Review</i> , 2018, 37, S206-S207. | 1.1 | 2 |
| 65 | A New Yearâ€”s Wish on Opioids. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 537. | 3.8 | 6 |
| 66 | Innovation and Entrepreneurship: Harnessing the Public Health Skill Set in a New Era of Health Reforms and Investment. <i>Journal of Public Health Management and Practice</i> , 2018, 24, 99-101. | 0.7 | 12 |
| 67 | Marylandâ€”s All-Payer Health Reformâ€”A Promising Work in Progress. <i>JAMA Internal Medicine</i> , 2018, 178, 269. | 2.6 | 9 |
| 68 | A Health Policy Sonnet. <i>Milbank Quarterly</i> , 2018, 96, 9-12. | 2.1 | 0 |
| 69 | Marylandâ€”s Hospital Global Budget Programâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2040. | 3.8 | 1 |
| 70 | Public Health Rising to the Challenge: The Bloomberg American Health Initiative. <i>Public Health Reports</i> , 2018, 133, 3S-4S. | 1.3 | 2 |
| 71 | The Fires Are Burning. <i>Milbank Quarterly</i> , 2018, 96, 623-626. | 2.1 | 0 |
| 72 | Common Ground on Health. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2518. | 3.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Global Budgets in Maryland. JAMA - Journal of the American Medical Association, 2018, 319, 2475. | 3.8 | 25 |
| 74 | How Do You Solve a Problem Like Juul?. Milbank Quarterly, 2018, 96, 417-420. | 2.1 | 1 |
| 75 | Crises and Population Health. Milbank Quarterly, 2018, 96, 223-226. | 2.1 | 0 |
| 76 | Emergency Department Utilization Among the Uninsured During Insurance Expansion in Maryland. Annals of Emergency Medicine, 2018, 72, 156-165. | 0.3 | 5 |
| 77 | The evidence and acceptability of taxes on unhealthy foods. Israel Journal of Health Policy Research, 2018, 7, 68. | 1.4 | 8 |
| 78 | The Opioid Crisis From Research to Practice. Milbank Quarterly, 2017, 95, 24-27. | 2.1 | 6 |
| 79 | Something new in the air: Paying for community-based environmental approaches to asthma prevention and control. Journal of Allergy and Clinical Immunology, 2017, 140, 1244-1249. | 1.5 | 11 |
| 80 | DÃ© Vu at the FDA. Milbank Quarterly, 2017, 95, 245-248. | 2.1 | 1 |
| 81 | Relationship Between the American Academy of Pediatrics and Infant Formula Companies. JAMA Pediatrics, 2017, 171, 613. | 3.3 | 9 |
| 82 | Marketing Claims for Infant Formula Additives and Infant Formula Reply. JAMA Pediatrics, 2017, 171, 811. | 3.3 | 0 |
| 83 | Vaccines and the Trump Administration. JAMA - Journal of the American Medical Association, 2017, 317, 1305. | 3.8 | 11 |
| 84 | Enhancing Transparency at the US Food and Drug Administration. JAMA - Journal of the American Medical Association, 2017, 317, 1621. | 3.8 | 12 |
| 85 | Marketing Claims for Infant Formula. JAMA Pediatrics, 2017, 171, 105. | 3.3 | 26 |
| 86 | Public Health Bundles. Milbank Quarterly, 2017, 95, 474-477. | 2.1 | 1 |
| 87 | Science and the Trump Administration. JAMA - Journal of the American Medical Association, 2017, 318, 1312. | 3.8 | 4 |
| 88 | Global Budgets for Safety-Net Hospitals. JAMA - Journal of the American Medical Association, 2017, 318, 1759. | 3.8 | 7 |
| 89 | US Hospital Awards and Community Health Improvement. American Journal of Public Health, 2017, 107, 1076-1077. | 1.5 | 2 |
| 90 | Power Morcellators, Postmarketing Surveillance, and the US Food and Drug Administration. JAMA - Journal of the American Medical Association, 2017, 318, 325. | 3.8 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Hospital Accreditation and Community Health. American Journal of Medicine, 2017, 130, 117-118. | 0.6 | 2 |
| 92 | Common Ground on Responsibility for Health. Milbank Quarterly, 2017, 95, 718-721. | 2.1 | 0 |
| 93 | Global Budgets for Rural Hospitals. Milbank Quarterly, 2016, 94, 255-259. | 2.1 | 13 |
| 94 | Rethinking Science and Politics. Milbank Quarterly, 2016, 94, 39-42. | 2.1 | 2 |
| 95 | A Stronger Treatment System for Opioid Use Disorders. JAMA - Journal of the American Medical Association, 2016, 315, 2165. | 3.8 | 9 |
| 96 | Promise and Peril for Generic Drugs. JAMA Internal Medicine, 2016, 176, 733. | 2.6 | 5 |
| 97 | Population Health Case Reports. JAMA - Journal of the American Medical Association, 2016, 315, 2663. | 3.8 | 13 |
| 98 | The Adequacy of Individual Hospital Data to Identify High Utilizers and Assess Community Health. JAMA Internal Medicine, 2016, 176, 856. | 2.6 | 12 |
| 99 | Breaking the gridlock: Regulation of dietary supplements in the United States. Drug Testing and Analysis, 2016, 8, 424-430. | 1.6 | 17 |
| 100 | Banishing "Stakeholders". Milbank Quarterly, 2016, 94, 476-479. | 2.1 | 12 |
| 101 | Pharmaceuticals and Public Health. JAMA - Journal of the American Medical Association, 2016, 316, 2083. | 3.8 | 4 |
| 102 | Violent Injury as a Preventable Condition. Milbank Quarterly, 2016, 94, 708-711. | 2.1 | 1 |
| 103 | Development of Maryland Local Overdose Fatality Review Teams. Health Promotion Practice, 2016, 17, 596-600. | 0.9 | 7 |
| 104 | Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion. JAMA - Journal of the American Medical Association, 2016, 315, 984. | 3.8 | 17 |
| 105 | Role of the FDA in Affordability of Off-Patent Pharmaceuticals. JAMA - Journal of the American Medical Association, 2016, 315, 461. | 3.8 | 22 |
| 106 | Dear Health Care Lobbyists . . . Milbank Quarterly, 2015, 93, 15-18. | 2.1 | 2 |
| 107 | An Update on Maryland's All-Payer Approach to Reforming the Delivery of Health Care. JAMA Internal Medicine, 2015, 175, 1083. | 2.6 | 17 |
| 108 | Electronic Cigarettes: Gateway to Understanding the FDA?. Milbank Quarterly, 2015, 93, 251-254. | 2.1 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 109 | Public Health and the First Amendment. <i>Milbank Quarterly</i> , 2015, 93, 459-462. | 2.1 | 1 |
| 110 | Accountability for Health. <i>Milbank Quarterly</i> , 2015, 93, 675-678. | 2.1 | 3 |
| 111 | On Fear, Distrust, and Ebola. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 784. | 3.8 | 13 |
| 112 | Achieving Health Equity by Design. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1417. | 3.8 | 54 |
| 113 | Maryland's Global Hospital Budgets "Preliminary Results from an All-Payer Model. <i>New England Journal of Medicine</i> , 2015, 373, 1899-1901. | 13.9 | 53 |
| 114 | FDA Regulation of Laboratory-Developed Diagnostic Tests. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 667. | 3.8 | 31 |
| 115 | Using Health Care Data to Track and Improve Public Health. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2012. | 3.8 | 8 |
| 116 | State Leadership in Health Care Transformation. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 349. | 3.8 | 6 |
| 117 | A Spotlight on Sunscreen Regulation. <i>New England Journal of Medicine</i> , 2015, 373, 101-103. | 13.9 | 8 |
| 118 | The Safety of Prescription Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 233. | 3.8 | 6 |
| 119 | Unrest in Baltimore. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2425. | 3.8 | 12 |
| 120 | Neurology and the Affordable Care Act. <i>JAMA Neurology</i> , 2015, 72, 623. | 4.5 | 4 |
| 121 | Of Mouse and Measles. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1504. | 3.8 | 2 |
| 122 | The Promotion of Medical Products in the 21st Century. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1795. | 3.8 | 8 |
| 123 | Working with Communities to Achieve Health Equity in Maryland's Five Health Enterprise Zones. <i>Journal of Health Care for the Poor and Underserved</i> , 2014, 25, 4-10. | 0.4 | 9 |
| 124 | Health Care and Poverty. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2200. | 3.8 | 1 |
| 125 | Maryland's All-Payer Approach to Delivery-System Reform. <i>New England Journal of Medicine</i> , 2014, 370, 493-495. | 13.9 | 85 |
| 126 | On Working for Henry Waxman. <i>Milbank Quarterly</i> , 2014, 92, 186-190. | 2.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 127 | Speaking With Doctors in Restaurants. <i>Milbank Quarterly</i> , 2014, 92, 422-425. | 2.1 | 0 |
| 128 | Chronic Pain, Addiction, and Zohydro. <i>New England Journal of Medicine</i> , 2014, 370, 2061-2063. | 13.9 | 24 |
| 129 | Confronting the Stigma of Opioid Use Disorder and Its Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1393. | 3.8 | 244 |
| 130 | Treatment for Opioid Use Disorder Reply. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 751. | 3.8 | 1 |
| 131 | Improving Medical Device Regulation. <i>JAMA Internal Medicine</i> , 2014, 174, 1779. | 2.6 | 3 |
| 132 | The Strange Journey of Population Health. <i>Milbank Quarterly</i> , 2014, 92, 640-643. | 2.1 | 23 |
| 133 | Critical Issues in US Health Care. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1945. | 3.8 | 1 |
| 134 | New Incentive-Based Programs. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 259. | 3.8 | 3 |
| 135 | A Systemic Approach to Containing Health Care Spending. <i>New England Journal of Medicine</i> , 2012, 367, 949-954. | 13.9 | 155 |
| 136 | Fungal Meningitis From Injection of Contaminated Steroids. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2461. | 3.8 | 17 |
| 137 | The FDA Safety and Innovation Act. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1437. | 3.8 | 5 |
| 138 | Toward Innovative Models of Health Care and Financing. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1261. | 3.8 | 9 |
| 139 | The FDA A Misunderstood Agency. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1250. | 3.8 | 3 |
| 140 | Transparency at the Food and Drug Administration. <i>New England Journal of Medicine</i> , 2010, 362, 2341-2343. | 13.9 | 33 |
| 141 | Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration. <i>New England Journal of Medicine</i> , 2010, 363, 1489-1491. | 13.9 | 136 |
| 142 | Tobacco Product Regulation A Public Health Approach. <i>New England Journal of Medicine</i> , 2010, 362, 1753-1756. | 13.9 | 60 |
| 143 | The FDA as a Public Health Agency. <i>New England Journal of Medicine</i> , 2009, 360, 2493-2495. | 13.9 | 66 |
| 144 | Over the Counter but No Longer under the Radar Pediatric Cough and Cold Medications. <i>New England Journal of Medicine</i> , 2007, 357, 2321-2324. | 13.9 | 134 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 145 | Kids First?. International Journal of Health Services, 2000, 30, 763-769. | 1.2 | 1 |
| 146 | Child health initiatives and journal narrow-mindedness. Lancet, The, 2000, 356, 1626. | 6.3 | 1 |
| 147 | Phenytoin Dosage. Pediatrics, 1998, 102, 1223-1223. | 1.0 | 3 |
| 148 | Campaign Contributions from the American Medical Political Action Committee to Members of Congress -- For or Against the Public Health?. New England Journal of Medicine, 1994, 330, 32-37. | 13.9 | 26 |
| 149 | The Development and Implementation of a New Hospital Performance Measure to Assess Hospital Contributions to Community Health and Equity. Health Services Research, 0, , . | 1.0 | 2 |